SCHEMBL23068144

SCHEMBL23068144

N#Cc1ccccc1OC1CC(c2ccccc2)CC1N1CCCC(N)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ TRPC3 Q13507 19/20 1.00
▸ TRPC6 Q9Y210 19/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21550286 1.00 TRPC3 (1.00) TRPC3TRPC6
SCHEMBL21550289 1.00 TRPC3 (1.00) TRPC3TRPC6
SCHEMBL30355281 0.86 TRPC3 (0.75) TRPC3TRPC6
SCHEMBL30355262 0.85 TRPC3 (0.75) TRPC3TRPC6
SCHEMBL30355214 0.85 TRPC6 (0.74) TRPC3TRPC6
SCHEMBL21550529 0.84 TRPC6 (1.00) TRPC3TRPC6
SCHEMBL23068102 0.84 TRPC3 (0.72) TRPC3TRPC6
SCHEMBL23068128 0.84 TRPC6 (1.00) TRPC3TRPC6
SCHEMBL30355258 0.79 TRPC3 (0.72) TRPC3TRPC6
SCHEMBL30355260 0.79 TRPC3 (0.72) TRPC3TRPC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12378218-B2 Cyclopentane compounds DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2025-08-05 — — US claimed
CN-112424182-B Cyclopentane compounds 迪哲(江苏)医药股份有限公司 2023-05-23 — — CN claimed
EP-3790870-B1 CYCLOPENTANE COMPOUNDS DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2023-04-19 — — EP claimed
WO-2021079962-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF HEARING LOSS 国立大学法人大阪大学 2021-04-29 — — WO claimed
US-20210070733-A1 CYCLOPENTANE COMPOUNDS DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2021-03-11 — — US claimed
CN-112424182-A Cyclopentane compounds 迪哲(江苏)医药股份有限公司 2021-02-26 — — CN claimed
US-12378218-B2 Cyclopentane compounds DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2025-08-05 — — US disclosed
CN-112424182-B Cyclopentane compounds 迪哲(江苏)医药股份有限公司 2023-05-23 — — CN disclosed
EP-3790870-B1 CYCLOPENTANE COMPOUNDS DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2023-04-19 — — EP disclosed
US-20220194922-A1 CYCLOPENTANE COMPOUNDS DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2022-06-23 — — US disclosed
US-11274091-B2 Cyclopentane compounds DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2022-03-15 — — US disclosed
WO-2021079962-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF HEARING LOSS 国立大学法人大阪大学 2021-04-29 — — WO disclosed
US-20210070733-A1 CYCLOPENTANE COMPOUNDS DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2021-03-11 — — US disclosed
US-20210070733-A1 CYCLOPENTANE COMPOUNDS DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2021-03-11 — — US disclosed
CN-112424182-A Cyclopentane compounds 迪哲(江苏)医药股份有限公司 2021-02-26 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12378218-B2 Cyclopentane compounds CYP11B2, CYP11B1, SQLE TRPC3 3056/4885TRPC6 3706/4885
US-20220194922-A1 CYCLOPENTANE COMPOUNDS CYP11B2, CYP11B1, SQLE TRPC3 3056/4885TRPC6 3706/4885
US-11274091-B2 Cyclopentane compounds CYP11B2, CYP11B1, SQLE TRPC3 3056/4885TRPC6 3706/4885
US-20210070733-A1 CYCLOPENTANE COMPOUNDS CYP11B2, CYP11B1, CYP51A1 TRPC3 2969/4885TRPC6 3415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback